Insight journal - Dealtalk

Ranbaxy Laboratories also looking to sell its vaccine business

Posted on 26 November 2013

Tags: , ,

Drug maker Ranbaxy Laboratories is likely to sell off Biovel, a Bangalore-based vaccine manufacturing company which it had acquired in 2010.

Although Ranbaxy made the acquisition to foray into the vaccine business, it failed to roll out any product in the segment for the past two years. The company recently booked impairment losses on account of Biovel.

During the July-September quarter, Ranbaxy's depreciation, amortisation and impairment were higher at Rs 133.4 crore, as against Rs 81.5 crore during the corresponding quarter the previous year. This was mainly on account of an exceptional impairment loss of Rs 48.5 crore registered by the company during the quarter with regard to the vaccine plant in Bangalore, the company management had told investors after announcing its July-September earnings in October. The company management had said the facility "is being impaired owing to prevalent market conditions".

Ranbaxy refused to comment on this. Biovel was working on biotechnology products in segments such as cardiology, endocrinology, oncology, dermatology and gynaecology, and also making typhoid and influenza vaccines in 2010, when it was acquired by Ranbaxy. The buyout was expected to mark the entry of Ranbaxy, owned by Japan's Daiichi Sankyo, into vaccines as well as biopharmaceuticals.

Read the full article on Business Standard

 

Related

Report: Asset Purchase Terms & Agreements

Report: Merger and Acquisition Terms and Agreements

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering |

Print Friendly, PDF & Email

Leave a Reply